Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that it has presented new pre-clinical data generated using its GalNAc-siRNA platform technology, including the translation of effective liver target knockdown into higher species, at the TIDES: Oligonucleotides and Peptide Therapeutics meeting in San Diego.
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
